

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (Currently amended) A isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) shown by the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing or by the complementary nucleotide sequence, or a polynucleotide (b) a nucleotide sequence encoding a protein shown by comprising the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or (c) a nucleotide sequence complementary to a polynucleotide defined in (a) or (b) a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide.
2. (Withdrawn) A polynucleotide shown by the nucleotide sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 5, in the sequence listing, or by the complementary nucleotide sequence, or a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 6 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide.
3. (Withdrawn) A polynucleotide containing a polynucleotide shown by the nucleotide sequence set forth in SEQ ID NO: 3, in the sequence listing or by the complementary nucleotide sequence, or a polynucleotide containing a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 4, in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide, wherein the polynucleotide encodes a protein that accelerates the activation of Cdc42.

4. (Cancelled)

5. (Currently amended) A An isolated polynucleotide with a mutation ~~or an induced mutation~~, such as deletion, substitution, or addition of one ~~or more~~ to ten nucleotides in the nucleotide sequence of the polynucleotide according to claim 1, wherein the polynucleotide encodes a protein that accelerates the activation of Cdc42.

6. (Currently amended) A An isolated polynucleotide that hybridizes to the polynucleotide according to claim 1 under stringent conditions, wherein the polynucleotide encodes a protein that accelerates the activation of Cdc42.

7. (Previously presented) A recombinant vector containing the polynucleotide according to claim 1.

8. (Original) A transformant that has been transfected with the recombinant vector according to claim 7.

9. (Original) A transformant that has been transfected with the recombinant vector according to claim 7, and a recombinant vector containing a polynucleotide encoding Cdc42.

10. (Withdrawn) A protein shown by the amino acid sequence set forth in SEQ ID NO: 2, in the sequence listing.

11. (Withdrawn) A protein shown by the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 6, in the sequence listing.
12. (Withdrawn) A protein encoded by the polynucleotide according to claim 3.
13. (Withdrawn) A method of producing the protein according to claim 10, comprising a step of culturing the transformant that has been transfected with a recombinant vector containing a polynucleotide shown by a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide.
14. (Withdrawn) An antibody that recognizes the protein according to claim 10.
15. (Withdrawn) A method of identifying a compound that inhibits the function of the proteins according to claim 10, and/or the expression of the polynucleotides shown by a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide, comprising detecting the presence, absence or change in the function and/or the expression under conditions where the interaction of a compound with the protein and/or the polynucleotide are allowed, and determining whether the compound inhibits the function of the protein and/or the expression of the polynucleotide.

16. (Withdrawn) The method according to claim 15, wherein the function of the protein is a function of binding to Cdc42 and/or a function of accelerating the activation of Cdc42.

17. (Withdrawn) A method of identifying a compound that inhibits the function of the protein according to claim 10 and/or the expression of a polynucleotide shown by a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide, comprising using at least one selected from the protein, a polynucleotide shown by a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide, a recombinant vector containing said polynucleotide, a transformant that has been transfected with the recombinant vector or an antibody that recognizes said protein.

18. (Withdrawn) The method according to claim 17, wherein the function of the proteins is a function of binding to Cdc42 and/or a function of accelerating the activation of Cdc42.

19. (Withdrawn) A method of determining whether a tissue specimen derived from a human stomach tissue is a tissue derived from a human stomach tumor or not, comprising measuring an amount of expression of the polynucleotide according to claim 1 in the tissue specimen.

20. (Withdrawn) The method according to claim 19, wherein the method determines that the tissue specimen is a tissue derived from a human stomach tumor in the case when the amount

of expression of the polynucleotide according to claim 1 in the tissue specimen is 4.5 times higher than that in a control tissue derived from normal human stomach tissue.

21. (Withdrawn) An agent for preventing and/or treating a stomach tumor, comprising a compound that inhibits the function of the protein according to claim 10 and/or a compound that inhibits the expression of the polynucleotide shown by a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide, as an effective ingredient.

22. (Withdrawn) A method of preventing and/or treating a stomach tumor, comprising using a compound that inhibits the function of the protein according to claim 10 and/or a compound that inhibits the expression of the polynucleotide shown by a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide.

23. (Currently amended) A reagent kit ~~containing~~ comprising at least one selected from the group consisting of: the protein according to claim 10, (a) a polynucleotide shown by a polynucleotide encoding a protein shown by comprising the amino acid sequence set forth in SEQ ID NO: 2; in the sequence listing, or (b) a polynucleotide comprising a shown by the complementary nucleotide sequence complementary to of the polynucleotide defined in (a); (c) a recombinant vector containing comprising said polynucleotide defined in (a) or (b); and (d) a transformant that has been transfected with the recombinant vector defined in (c), or an antibody

U.S. Patent Application No. 10/594,707
Amendment dated December 30, 2008
Reply to Office Action of October 15, 2008

~~that recognizes said protein.~~